Number (%) of ACR20–ACR50–ACR70 responders by treatment and visit up to week 16, last observation carried forward (full analysis set)
| Secukinumab | Placebo N=50 n/N′ (%) | ||||
|---|---|---|---|---|---|
| 25 mg N=53* n/N′ (%) | 75 mg N=49 n/N′ (%) | 150 mg N=43 n/N′ (%) | 300 mg N=41 n/N′ (%) | ||
| Week 2 | |||||
| ACR20 | 9/52 (17.3) | 9/49 (18.4) | 9/43 (20.9) | 7/40 (17.5) | 3/49 (6.1) |
| ACR50 | 2/52 (3.8) | 2/49 (4.1) | 2/43 (4.7) | 0/40 | 1/49 (2.0) |
| ACR70 | 0/52 | 0/49 | 0/43 | 0/40 | 0/49 |
| Week 4 | |||||
| ACR20 | 13/53 (24.5) | 12/49 (24.5) | 13/43 (30.2) | 7/41 (17.1) | 8/50 (16.0) |
| ACR50 | 2/53 (3.8) | 2/49 (4.1) | 1/43 (2.3) | 0/41 | 2/50 (4.0) |
| ACR70 | 1/53 (1.9) | 1/49 (2.0) | 1/43 (2.3) | 0/41 | 0/50 |
| Week 8 | |||||
| ACR20 | 15/53 (28.3) | 22/49 (44.9) | 17/43 (39.5) | 16/41 (39.0) | 11/50 (22.0) |
| ACR50 | 6/53 (11.3) | 6/49 (12.2) | 5/43 (11.6) | 3/41 (7.3) | 1/50 (2.0) |
| ACR70 | 2/53 (3.8) | 2/49 (4.1) | 1/43 (2.3) | 1/41 (2.4) | 0/50 |
| Week 12 | |||||
| ACR20 | 17/53 (32.1) | 25/49 (51.0) | 24/43 (55.8) | 20/41 (48.8) | 12/50 (24.0) |
| ACR50 | 4/53 (7.5) | 8/49 (16.3) | 7/43 (16.3) | 6/41 (14.6) | 1/50 (2.0) |
| ACR70 | 3/53 (5.7) | 2/49 (4.1) | 2/43 (4.7) | 1/41 (2.4) | 0/50 |
| Week 16 | |||||
| ACR20 | 18/53 (34.0) | 23/49 (46.9) | 20/43 (46.5) | 22/41 (53.7) | 18/50 (36.0) |
| ACR50 | 8/53 (15.1) | 9/49 (18.4) | 9/43 (20.9) | 7/41 (17.1) | 3/50 (6.0) |
| ACR70 | 4/53 (7.5) | 1/49 (2.0) | 2/43 (4.7) | 2/41 (4.9) | 0/50 |
*One patient was excluded from the full analysis due to insufficient efficacy assessments.
ACR, American College or Rheumatology; n, number of subjects who are responders at the corresponding category; N′, the total number of subjects with non-missing ACR evaluation at the corresponding category and specific visit.